| Filed On | Filing |
|---|---|
| 23 Jan 2023 |
8-K/A: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1: Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors (the “Board”) of Neoleukin Therapeutics, Inc. (the... |
| 17 Dec 2019 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference in Registration Statement Nos. 333-194490, 333-203179, 333-210172, 333-216572, 333-223589 and 333-234734 on Form S-8 and Nos. 333-203180, 333-208651, 333-215457 and 333-223584 on Form S-3 of o... |
| 11 Oct 2019 |
8-K/A: Financial Statements and Exhibits
On August 8, 2019, Aquinox Pharmaceuticals, Inc. (“Aquinox”), completed its acquisition of Neoleukin Therapeutics, Inc., a Delaware corporation (“Former Neoleukin”), pursuant to the terms of an Agreement and Plan of Merger (the “Merger A... |
| 07 Aug 2015 |
8-K/A: Other Events
Vancouver, British Columbia - August 6, 2015 - (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ: AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of infl... |
Loading...